661 related articles for article (PubMed ID: 2250704)
21. Transformation of bone marrow cells from E mu-myc transgenic mice by Abelson murine leukemia virus and Harvey murine sarcoma virus.
Dyall-Smith D; Cory S
Oncogene Res; 1988 May; 2(4):403-9. PubMed ID: 2840624
[TBL] [Abstract][Full Text] [Related]
22. A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice.
Nussenzweig MC; Schmidt EV; Shaw AC; Sinn E; Campos-Torres J; Mathey-Prevot B; Pattengale PK; Leder P
Nature; 1988 Dec; 336(6198):446-50. PubMed ID: 3143076
[TBL] [Abstract][Full Text] [Related]
23. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death.
Korsmeyer SJ; Shutter JR; Veis DJ; Merry DE; Oltvai ZN
Semin Cancer Biol; 1993 Dec; 4(6):327-32. PubMed ID: 8142617
[TBL] [Abstract][Full Text] [Related]
24. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.
Nuñez G; London L; Hockenbery D; Alexander M; McKearn JP; Korsmeyer SJ
J Immunol; 1990 May; 144(9):3602-10. PubMed ID: 2184193
[TBL] [Abstract][Full Text] [Related]
25. Oligonucleotides induce apoptosis restricted to the t(14;18) DHL-4 cell line.
Morelli S; Alama A; Quattrone A; Gong L; Copreni E; Canti G; Nicolin A
Anticancer Drug Des; 1996 Jan; 11(1):1-14. PubMed ID: 8639245
[TBL] [Abstract][Full Text] [Related]
26. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors.
Klein G
AIDS Res; 1986 Dec; 2 Suppl 1():S167-76. PubMed ID: 3030345
[TBL] [Abstract][Full Text] [Related]
27. Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1989; 4(4):253-8. PubMed ID: 2549487
[TBL] [Abstract][Full Text] [Related]
28. Analysis of BCL2 and MYC expression in non-Hodgkin's lymphomas by in situ hybridization: correlation with chromosome translocations.
Murty VV; Ladanyi M; Houldsworth J; Mikraki V; Chaganti RS
Diagn Mol Pathol; 1992 Dec; 1(4):221-8. PubMed ID: 1342969
[TBL] [Abstract][Full Text] [Related]
29. Cooperative interaction between c-myc and bcl-2 proto-oncogenes.
Fanidi A; Harrington EA; Evan GI
Nature; 1992 Oct; 359(6395):554-6. PubMed ID: 1406976
[TBL] [Abstract][Full Text] [Related]
30. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18).
McDonnell TJ; Korsmeyer SJ
Nature; 1991 Jan; 349(6306):254-6. PubMed ID: 1987477
[TBL] [Abstract][Full Text] [Related]
31. Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1.
Denyssevych T; Lestou VS; Knesevich S; Robichaud M; Salski C; Tan R; Gascoyne RD; Horsman DE; Mayer LD
Leukemia; 2002 Feb; 16(2):276-83. PubMed ID: 11840295
[TBL] [Abstract][Full Text] [Related]
32. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV.
Zörnig M; Grzeschiczek A; Kowalski MB; Hartmann KU; Möröy T
Oncogene; 1995 Jun; 10(12):2397-401. PubMed ID: 7784089
[TBL] [Abstract][Full Text] [Related]
33. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice.
Linden M; Kirchhof N; Kvitrud M; Van Ness B
Leuk Res; 2005 Apr; 29(4):435-44. PubMed ID: 15725478
[TBL] [Abstract][Full Text] [Related]
34. Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas.
Martín-Subero JI; Odero MD; Hernandez R; Cigudosa JC; Agirre X; Saez B; Sanz-García E; Ardanaz MT; Novo FJ; Gascoyne RD; Calasanz MJ; Siebert R
Genes Chromosomes Cancer; 2005 Aug; 43(4):414-23. PubMed ID: 15852472
[TBL] [Abstract][Full Text] [Related]
35. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc.
Allen JD; Verhoeven E; Domen J; van der Valk M; Berns A
Oncogene; 1997 Sep; 15(10):1133-41. PubMed ID: 9294606
[TBL] [Abstract][Full Text] [Related]
36. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
Smith DP; Bath ML; Harris AW; Cory S
Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
[TBL] [Abstract][Full Text] [Related]
37. Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector.
Adams JM; Harris AW; Strasser A; Ogilvy S; Cory S
Oncogene; 1999 Sep; 18(38):5268-77. PubMed ID: 10498879
[TBL] [Abstract][Full Text] [Related]
38. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
Roland J; Morello D
Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective.
Gaidano G; Pastore C; Volpe G
Haematologica; 1995; 80(5):454-72. PubMed ID: 8566891
[TBL] [Abstract][Full Text] [Related]
40. Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation.
McNeil N; Kim JS; Ried T; Janz S
Genes Chromosomes Cancer; 2005 Jun; 43(2):137-46. PubMed ID: 15751044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
